Noxopharm Ltd has released a press release.
Noxopharm Targets Clinical Trial for First-in-Class Drug
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Significant CRO-67 Results in Pancreatic Cancer Studies
- June 2024 Quarterly Activities Report and Appendix 4C
- March 2024 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2024 Financial Report
- December 2023 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- Significant results from new brain cancer drugs
- Advanced funding secured ahead of R&D rebate
- New funding from sophisticated investors
- September 2024 Quarterly Activities report and Appendix 4C
- Additional convertible note for long-term shareholder
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm